Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg

Phase 1

Completed

• Conditions: PAH
• Interventions: Drug: Macitentan and Tadalafil; Drug: PrOpsynvi® Film-Coated Tablets

• Registration Number: NCT06553937
• Lead Sponsor: Humanis Saglık Anonim Sirketi

Brief Summary

Single dose oral bioequivalence study of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil film-coated tablets 10 mg/40 mg in healthy adult male subjects under fed conditions.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-10
• Primary Completion: 2024-06-03
• Study Completion: 2024-07-31
• Status Verified: 2024-08
• Study First Submitted: 2024-08-12
• Study First Submitted QC: 2024-08-13
• Last Update Submitted: 2024-08-13
• Study First Posted: 2024-08-14
• Last Update Posted: 2024-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Volunteers must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified.

1. Age: 18 to 55 years old, both inclusive. 2) Gender: Male. 3) BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5). 4) Non-smokers and non-tobacco users (i.e. having no past history of smoking and tobacco consuming for at least one year prior to study).

2. Able to communicate effectively with study personnel. 6) Willing to provide written informed consent to participate in the study. 7) All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include:

1. A physical examination (clinical examination) with no clinically significant finding.

2. Results within normal limits or clinically non-significant for the following tests: Hematology Hemoglobin Total RBC count Total WBC count Platelet count

   Differential leukocyte count:

   Neutrophils Lymphocytes Eosinophils Monocytes Basophils Blood indices: HCT Biochemistry BUN, Serum creatinine, Random glucose, SGPT & SGOT Alkaline phosphatase Uric acid Serum bilirubin Serum total protein: Total proteins, Albumin Serum electrolytes: Serum sodium, serum chloride, serum potassium, serum phosphorous, serum calcium Urinalysis Color, quantity, specific gravity, odour, appearance, reaction, albumin, bilirubin, ketone bodies, sugar, urobilinogen and microscopical examination (performed based on clinical judgment) Immunological Tests HIV-I & II, HbsAg ,Anti HCV

   • Additional tests and/or examinations (apart from mentioned in protocol) may be performed, if necessary, based on principal investigator discretion.
   • All results will be assessed against the current laboratory normal ranges at the time of testing and a copy of the normal ranges used will be included in the study documentation.

   EXCLUSION CRITERIA

   Volunteers must not be enrolled in the study if they meet any one of the following criteria:

   1. History of allergic responses to Macitentan, Tadalafil or other related drugs, or any of its formulation ingredients.

   Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, ECG recording].

   3. Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.

   4. History or presence of bronchial asthma. 5) Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.

   5. Use of any depot injection or implant of any drug within 3 months prior to the first dose of study medication.

   6. Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see https://drug interactions.medicine.iu.edu/MainTable.aspx). 8) History or evidence of drug dependence or of alcoholism or of moderate alcohol use.

   7. History of difficulty with donating blood or difficulty in accessibility of veins.

   8. A positive hepatitis screen (includes subtypes B & C). 11) A positive test result for HIV antibody. 12) Volunteers who have received an investigational drug within 90 days prior to the first dose of study medication.

   9. Volunteers who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.

   10. History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.

   11. Intolerance to venipuncture 16) Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.

   12. Institutionalized volunteers. 18) Use of any prescribed medications [Including guanylate cyclase stimulators, such as riociguat and potent CYP3A4 inhibitors (e.g. ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin)] within 14 days prior to the first dose of study medication.

   13. Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.

   14. Use of grapefruit and grapefruit containing products within 7 days prior to the first döşe of study medication.

   Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeinecontaining sodas, colas, etc.), recreational drugs, alcohol or other alcohol containing products, dietary items that have effect on P450 enzymes (e.g. pomegranate, star fruit, seville oranges) & PGP (P-Glycoprotein) efflux pump (e.g. St. John's wort) within 48 hours prior to the first dose of study medication.

   22. Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.

   23. Use of any form of organic nitrate. 24) History of myocardial infarction, unstable angina or angina, heart failure, uncontrolled arrhythmias, hypotension, uncontrolled hypertension or stroke.

   24. Presence of anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease).

   25. History or presence of benign prostatic hyperplasia. 27) History of vision loss or optic neuropathy. 28) Volunteer having Hemoglobin value lower than the lower limit of normal range during screening.

   26. SGPT, SGOT and alkaline phosphatase values 1.1 times higher than the upper limit of normal range during screening.

   27. Serum bilirubin value higher than the upper limit of normal range during screening.

   28. History of heart failure, pulmonary edema, fluid retention/peripheral edema, or chronic liver disease.

   29. History of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Macitentan and Tadalafil	Macitentan and Tadalafil	Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Macitentan and Tadalafil	PrOpsynvi® Film-Coated Tablets	Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
PrOpsynvi® film-coated tablets	Macitentan and Tadalafil	PrOpsynvi® film-coated tablets10 mg/40 mg
PrOpsynvi® film-coated tablets	PrOpsynvi® Film-Coated Tablets	PrOpsynvi® film-coated tablets10 mg/40 mg

Primary Outcome Measures

Name	Time	Method
Maximum concentration obtained (Cmax)	72 hours	two-sided 90% CI for the test to reference ratio of the population means is within 80.00 - 125.00% for each of the Ln-transformed data Cmax
AUC from time 0 to last collection time t (AUC0-t)	72 hours	two-sided 90% CI for the test to reference ratio of the population means is within 80.00 - 125.00% for each of the Ln-transformed data AUC0-t

Secondary Outcome Measures

Name	Time	Method
AUC from time 0 to infinity (AUCt-∞)	72 hours	Descriptive Statistics
Time to reach maximum concentration Cmax (Tmax)	72 hours	Descriptive Statistics

Trial Locations

Locations (1)

Cliantha Research Limited; 🇮🇳 Ahmedabad, Gujarat, India